MX2022010218A - Anticuerpo anti-il-2 y fragmento de union a antigeno del mismo y su uso medico. - Google Patents

Anticuerpo anti-il-2 y fragmento de union a antigeno del mismo y su uso medico.

Info

Publication number
MX2022010218A
MX2022010218A MX2022010218A MX2022010218A MX2022010218A MX 2022010218 A MX2022010218 A MX 2022010218A MX 2022010218 A MX2022010218 A MX 2022010218A MX 2022010218 A MX2022010218 A MX 2022010218A MX 2022010218 A MX2022010218 A MX 2022010218A
Authority
MX
Mexico
Prior art keywords
antigen
antibody
binding fragment
medical use
complex
Prior art date
Application number
MX2022010218A
Other languages
English (en)
Inventor
Yuan Lin
Cheng Liao
Fuxiang Zhu
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2022010218A publication Critical patent/MX2022010218A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona un anticuerpo anti-IL-2, un fragmento de unión a antígeno del mismo y el uso médico del mismo. También se proporciona un complejo (que incluye una proteína de fusión) del anticuerpo anti-IL-2, su fragmento de unión a antígeno e IL-2, y el uso del complejo como fármaco para tratar enfermedades autoinmunes y enfermedades inflamatorias.
MX2022010218A 2020-02-21 2021-02-19 Anticuerpo anti-il-2 y fragmento de union a antigeno del mismo y su uso medico. MX2022010218A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010107662 2020-02-21
PCT/CN2021/076806 WO2021164722A1 (zh) 2020-02-21 2021-02-19 抗il-2抗体、其抗原结合片段及其医药用途

Publications (1)

Publication Number Publication Date
MX2022010218A true MX2022010218A (es) 2022-09-19

Family

ID=77390419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010218A MX2022010218A (es) 2020-02-21 2021-02-19 Anticuerpo anti-il-2 y fragmento de union a antigeno del mismo y su uso medico.

Country Status (11)

Country Link
US (1) US20230089620A1 (es)
EP (1) EP4108683A4 (es)
JP (1) JP2023515480A (es)
KR (1) KR20220143869A (es)
CN (1) CN115210257A (es)
AU (1) AU2021223063A1 (es)
BR (1) BR112022016326A2 (es)
CA (1) CA3169980A1 (es)
MX (1) MX2022010218A (es)
TW (1) TW202140563A (es)
WO (1) WO2021164722A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539749A (ja) * 2021-10-14 2024-10-29 ラッティコン （スージョウ） バイオファーマシューティカルズ カンパニー リミテッド 新規な抗体－サイトカイン融合タンパク質及びその製造方法と使用
CN115850471A (zh) * 2022-10-13 2023-03-28 深圳市百士通科技开发有限公司 一种抗人il-2单克隆抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
ATE395413T1 (de) 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
PT2334705T (pt) 2008-09-26 2017-03-22 Ucb Biopharma Sprl Produtos biológicos
WO2014028748A1 (en) * 2012-08-15 2014-02-20 Irm Llc Interleukin 2 antibodies and antibody complexes
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
CN115636880A (zh) 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
CN115073581A (zh) * 2016-05-04 2022-09-20 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
KR102692379B1 (ko) * 2017-06-05 2024-08-05 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 사용 방법
WO2019168791A2 (en) * 2018-02-28 2019-09-06 The Board Of Trustees Of The Leland Stanford Junior University Single-chain il-2/antibody fusions that selectively activate regulatory t cells

Also Published As

Publication number Publication date
US20230089620A1 (en) 2023-03-23
BR112022016326A2 (pt) 2022-10-11
AU2021223063A1 (en) 2022-09-29
CA3169980A1 (en) 2021-08-26
CN115210257A (zh) 2022-10-18
WO2021164722A1 (zh) 2021-08-26
TW202140563A (zh) 2021-11-01
EP4108683A1 (en) 2022-12-28
KR20220143869A (ko) 2022-10-25
JP2023515480A (ja) 2023-04-13
EP4108683A4 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
MY208638A (en) Anti-steap1 antigen-binding protein
EP4424324A3 (en) Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
CA3010621A1 (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
MX2020010458A (es) Conjugados de camptotecina-peptido.
MX2022003930A (es) Conjugados de péptido de camptotecina.
CO2020013252A2 (es) Dosificación subcutánea de anticuerpos anti-cd38
MX2021000083A (es) Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
JOP20220071A1 (ar) سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15Ra
MX2021001143A (es) Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
SA523451800B1 (ar) Sirp أجسام مضادة لـ ألفا
NZ770219A (en) Monoclonal antibodies against human tim-3
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
MX2023010567A (es) Variantes de anticuerpos no activadoras.
MX2022010218A (es) Anticuerpo anti-il-2 y fragmento de union a antigeno del mismo y su uso medico.
ZA202003320B (en) Glucuronylation as acidic post-translational modification on therapeutic monoclonal antibodies
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
ZA202309150B (en) Antibody against nkp46 and application of antibody
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.